Repatha is now available for a monthly cash price of $239, through AmgenNow and GoodRx. Repatha (evolucumab) is now avaliable ...
GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the availability of Repatha® ...
Amgen announced the launch of its direct-to-patient program providing eligible patients discounted pricing for evolocumab, a ...
Amgen will offer its lipid-lowering drug Repatha directly to patients for $239 per month, representing a nearly 60% reduction ...
US biotech major Amgen is the latest drugmaker to announce direct-to-consumer access of medicines, adding to the first such ...
Repatha (evolocumab) is an injectable medicine that helps lower levels of low-density lipoprotein cholesterol (LDL), often called “bad” cholesterol. Approved in 2015, Repatha can now be used in adults ...
THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to ...
Previously, Repatha was indicated to reduce the risk of MACE in patients with established cardiovascular disease. The Food and Drug Administration (FDA) has expanded the approval of Repatha ® ...
The FDA has expanded approval of Amgen’s PCSK9 inhibitor Repatha (evolocumab), permitting use in adults at increased risk of major adverse cardiovascular events due to uncontrolled LDL cholesterol, ...
Findings from the Phase III VESALIUS-CV study reinforce the cholesterol-lowering benefit of Repatha in high-risk patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback